Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1157)	6/27/2005 10:09:56 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

EPIX is going over its May 11 H of 8.99 and seems it should be able to test its Feb. 9 H at 9.67,but wether it will be able to close some of its downgap on Jan. 14 is a different question.<g> bigcharts.marketwatch.com News today about the CHMP adopting a positive opinion on Vasovist for contrast-enhanced MR angiography for patients with abdominal or lower limb vessels arterial disease. "This is a significant regulatory milestone for the MS-325 program," said Michael D. Webb, CEO of EPIX. "We expect that the European marketing authorization for Vasovist will be granted later this year. biz.yahoo.com Bernard